Alliance Pharma Positive Despite First-Half Challenges
Executive Summary
Alliance Pharma is anticipating strong sales growth in the second half of the year as its overcomes the supply chain and lockdown challenges that held back its first half performance.
You may also be interested in...
People On The Move: Appointments At Alliance Pharma, Venture Life, Maxwellia
A round-up of the latest European consumer health industry appointments: Alliance Pharma names Jo LeCouilliard as chair; Venture Life hires Paul McGreevy as non-executive chair; and Maxwellia appoints Ian Adamson as a strategic advisor.
Alliance Pharma Enhances US Offering With Perrigo's Scar Treatments
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
Alliance Pharma Eyes OTC Acquisitions Following Strong 2021
UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.